Switch View
© PR Newswire
08.11.2025
ISIN: US6402683063
Nektar Therapeutics
NKTR
LISTED
NASDAQ
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
News Preview
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma
Extended dosing with rezpegaldesleukin q2w supports 24-week induction peri...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2025
ISIN: US92532F1003
Vertex Pharmaceuticals Inc
VRTX
LISTED
NASDAQ
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic an...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US4577301090
Inspire Medical Systems Inc
INSP
LISTED
NYSE
INSP Investors Have Opportunity to Lead Inspire Medical Systems, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 8, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
08.11.2025
ISIN: US02043Q1076
Alnylam Pharmaceuticals Inc
ALNY
LISTED
NASDAQ
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneu...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
08.11.2025
ISIN: US45826J1051
Intellia Therapeutics Inc
NTLA
LISTED
NASDAQ
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
News Preview
CAMBRIDGE, Mass., Nov. 08, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented positive clinical data from a pooled analysis of all patients who received a 50 milligram (mg) dose of lonvo-z in the company...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in a statist...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2025
ISIN: US5288723027
Lexicon Pharmaceuticals Inc
LXRX
LISTED
NASDAQ
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
News Preview
Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2025
ISIN: US4577301090
Inspire Medical Systems Inc
INSP
LISTED
NYSE
Important Notice to Long-Term Shareholders of Inspire Medical Systems, Inc. (INSP): Grabar Law Office Is Investigating Claims on Your Behalf
News Preview
Philadelphia, Pennsylvania--(Newsfile Corp. - November 8, 2025) - Grabar Law Office is investigating claims on behalf of Inspire Medical Systems, Inc. (NYSE: INSP) shareholders. The investigation concerns whether certain officers of Inspire Medical have breached their fiduciary duties owed to the company.Current Inspire Medical shareholders who hav...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions
News Preview
STOCKHOLM, Nov. 8, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that, the TIMI Study Group today has presented positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) at the American Heart Association 2025 Scientific Sessions. The s...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2025
ISIN: US61225M1027
Monte Rosa Therapeutics Inc
GLUE
LISTED
NASDAQ
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
News Preview
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2025
ISIN: US87990A1060
Tenaya Therapeutics Inc
TNYA
LISTED
NASDAQ
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
News Preview
MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US0311621009
Amgen Inc
AMGN
LISTED
NASDAQ
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
News Preview
Study Also Shows 36% Reduction in Risk of Heart Attack
Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNew...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
08.11.2025
ISIN: US0080642061
Jade Biosciences Inc
JBIO
LISTED
NASDAQ
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
News Preview
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today presented two posters for JADE101, its investigational anti-A PRoliferation-Inducing...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2025
ISIN: US75886F1075
Regeneron Pharmaceuticals Inc
REGN
LISTED
NASDAQ
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
News Preview
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
News Preview
- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated:...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2025
ISIN: US4622221004
Ionis Pharmaceuticals Inc
IONS
LISTED
NASDAQ
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). The studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride (TG) le...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2025
ISIN: CH0334081137
CRISPR Therapeutics AG
CRSP
LISTED
NASDAQ
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
News Preview
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025-...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2025
ISIN: US4718712023
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
JSPR DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action - JSPR
News Preview
New York, New York--(Newsfile Corp. - November 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline.SO WHAT:...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2025
ISIN: US68622V1061
Organon & Co
OGN
LISTED
NYSE
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
News Preview
Organon (NYSE: OGN), a global independent healthcare company with a focus on women’s health, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Orla...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX DEADLINE: MoonLake Immunotherapeutics Investors with Losses are Notified to Contact BFA Law before December 15 Securities Class Action Deadline
News Preview
New York, New York--(Newsfile Corp. - November 8, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are e...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
DXCM DEADLINE: DexCom, Inc. Investors with Losses are Notified to Contact BFA Law before December 26 Securities Class Action Deadline
News Preview
New York, New York--(Newsfile Corp. - November 8, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from the potential violations of the...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.11.2025
ISIN: US51654W1018
Lantern Pharma Inc.
LTRN
LISTED
NASDAQ
New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST
News Preview
NEW YORK CITY, NEW YORK / ACCESS Newswire / November 8, 2025 / New to The Street announces the broadcast of Show Number 698, airing on Bloomberg Television this Saturday, November 8, 2025, at 6:30 PM EST, as sponsored programming.This week's show features exclusive interviews and insights from leading companies and financial professionals:Lantern P...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2025
ISIN: DK0062498333
Novo Nordisk A/S
NOVO B
LISTED
CPH
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
News Preview
Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera....
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Cytokinetics between December 27, 2023...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Baxter between February 23...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in aTyr between January 16, 2025 and September 12...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Molina Healthcare
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Molina To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Molina between February 5, 2025 and July 23,...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Lantheus between February 26, 2025 and Aug...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in MoonLake between March 10, 2024 and Septem...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Avantor
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Avantor To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Avantor between March 5, 2024 and October 28, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
News Preview
SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Peters v. MoonLake Immunotherapeutics, No. 25-cv-08612 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) com...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US1598641074
Charles River Laboratories International Inc
CRL
LISTED
NYSE
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
News Preview
NEW YORK and NEW ORLEANS, Nov. 7, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Charles River Laboratories International, Inc. ("Charles River" or the "C...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US68622V1061
Organon & Co
OGN
LISTED
NYSE
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
News Preview
NEW YORK and NEW ORLEANS, Nov. 7, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), is investigating claims on behalf of investors of Organon & Co. (NYSE: OGN). Such investors are advised to contact KSF Manag...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Molina Healthcare, Inc. - MOH
News Preview
NEW YORK and NEW ORLEANS, Nov. 7, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have untilDecember 2, 2025 to file lead plaintiff applications in a securities class action lawsuit against Molina Healt...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK
News Preview
NEW YORK and NEW ORLEANS, Nov. 7, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have untilNovember 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetic...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SVRA
News Preview
New York, New York--(Newsfile Corp. - November 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the "Class Period"), of the important November 7, 2025 lead plaintiff deadline.SO WHAT: If you purchased S...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US59267L1070
Metsera, Inc.
MTSR
LISTED
NASDAQ
Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer
News Preview
Revised transaction values Metsera at up to $86.25 per share
Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LANTHEUS DEADLINE: ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action - LNTH
News Preview
New York, New York--(Newsfile Corp. - November 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important November 10, 2025 lead plaintiff deadline.SO WHAT:...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH FINAL DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Molina Healthcare, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOH
News Preview
New York, New York--(Newsfile Corp. - November 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), of the important December 2, 2025 lead plaintiff deadline.SO WHAT: If you pur...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare, Inc. (MOH) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
LOS ANGELES, Nov. 7, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE: MOH) have opportunity to lead the securities fraud class action lawsuit....
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
LOS ANGELES, Nov. 7, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) have opportunity to lead the securities fraud class action lawsuit....
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US8342033094
Soleno Therapeutics Inc
SLNO
LISTED
NASDAQ
SLNO INVESTIGATION ALERT: Investigation Launched into Soleno Therapeutics, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
News Preview
SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ: SLNO) focused on whether Soleno and certain of its top executives made false and/or misleading statements and/or failed to...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAX
News Preview
New York, New York--(Newsfile Corp. - November 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WHAT:...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
ROSEN, A LEADING LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
News Preview
New York, New York--(Newsfile Corp. - November 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.SO WHAT: I...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR
News Preview
New York, New York--(Newsfile Corp. - November 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Avantor, Inc. (NYSE: AVTR) between March 5, 2024 and October 28, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
BENSALEM, Pa., Nov. 7, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR).
IF YOU ARE AN INV...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
Baxter International, Inc. (BAX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
BENSALEM, Pa., Nov. 7, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX).
IF YOU A...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 7, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2025
ISIN: US4577301090
Inspire Medical Systems Inc
INSP
LISTED
NYSE
Rosen Law Firm Urges Inspire Medical Systems, Inc. (NYSE: INSP) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Inspire Medical Systems, Inc. (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”). Inspire Medical is a medical technology company.
For more information, submit a f...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
ISIN: US34965K1079
Fortrea Holdings Inc
FTRE
LISTED
NASDAQ
Fortrea Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortrea Holdings, Inc. - FTRE
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fortrea Holdings, Inc. (NasdaqGS: FTRE).
In June 2023, Fortrea was spun off into a standalone, publicly traded company by Labcorp Holdings Inc. In connection with...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
Class Action Reminder: AVTR Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Avantor, Inc. Class Action Lawsuit
News Preview
SAN DIEGO, Nov. 7, 2025 /PRNewswire/ --
Company: Avantor, Inc. (NYSE: AVTR) provides scientific products and services for customers in biotech...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2025
ISIN: US4577301090
Inspire Medical Systems Inc
INSP
LISTED
NYSE
Stockholder Alert: Robbins LLP Informs Investors of the Inspire Medical Systems, Inc. Class Action Lawsuit
News Preview
SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Inspire Medical Systems, Inc. (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025. Inspire is a medical technology company....
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
ISIN: US38341P1021
Gossamer Bio Inc
GOSS
LISTED
NASDAQ
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
ISIN: US92337R1014
Vera Therapeutics Inc
VERA
LISTED
NASDAQ
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
News Preview
Vera Therapeutics Submits BLA to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgAN...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
ISIN: US6031701013
Mineralys Therapeutics Inc
MLYS
LISTED
NASDAQ
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
News Preview
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
ISIN: US74587V1070
Puma Biotechnology Inc
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 11,250 shares of Puma common stock to two new non-executive employees.
The awards were granted under Puma’s 2017 Em...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Deadline Soon: Lantheus Holdings, Inc. (LNTH) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming November 10, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusi...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
ISIN: IL0006290147
Teva Pharmaceutical Industries Ltd
TEVA
LISTED
TLV
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
News Preview
PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new data from the ongoing, real-world IMPACT-TD Registry. The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2025
ISIN: US29350E2037
Lunai Bioworks Inc.
LNAI
LISTED
NASDAQ
Lunai Bioworks schafft es, sowohl primäre als auch metastasierte Bauchspeicheldrüsentumoren in präklinischen humanisierten Modellen komplett zurückzubilden, was einen Durchbruch in der allogenen Krebsimmuntherapie bedeutet
News Preview
Lunai Bioworks gibt die Veröffentlichung der allogenen dendritischen Zelltherapieplattform der zweiten Generation in der Fachzeitschrift „Vaccines" bekannt.
LOS ANGELES, 7. November 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), ein KI-gestütztes Unternehmen für Arzneimittelforschung und Bioa...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
Deadline Approaching: Avantor, Inc. (AVTR) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming December 29, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR) common stock between March 5, 2024 and October 28, 2025, inclusive (the “Class Period”).
IF YOU ARE AN INVESTOR W...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
